Biltmore Family Office LLC Has $1.32 Million Holdings in iShares Biotechnology ETF (NASDAQ:IBB)

Biltmore Family Office LLC decreased its position in iShares Biotechnology ETF (NASDAQ:IBB) by 1.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,040 shares of the financial services provider’s stock after selling 125 shares during the quarter. Biltmore Family Office LLC’s holdings in iShares Biotechnology ETF were worth $1,316,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of IBB. Darwin Wealth Management LLC bought a new position in iShares Biotechnology ETF in the third quarter valued at $29,000. Highline Wealth Partners LLC acquired a new position in shares of iShares Biotechnology ETF during the 3rd quarter worth about $30,000. Bbjs Financial Advisors LLC acquired a new position in shares of iShares Biotechnology ETF during the 2nd quarter worth about $31,000. Ashton Thomas Securities LLC bought a new position in shares of iShares Biotechnology ETF in the 3rd quarter valued at about $36,000. Finally, Voisard Asset Management Group Inc. acquired a new stake in shares of iShares Biotechnology ETF in the third quarter valued at about $59,000. 62.45% of the stock is currently owned by institutional investors.

iShares Biotechnology ETF Trading Up 0.9 %

IBB opened at $136.10 on Friday. The business’s 50-day simple moving average is $143.63 and its 200 day simple moving average is $141.71. iShares Biotechnology ETF has a 52-week low of $117.28 and a 52-week high of $150.57.

iShares Biotechnology ETF Announces Dividend

The business also recently disclosed a dividend, which was paid on Monday, September 30th. Stockholders of record on Wednesday, September 25th were paid a dividend of $0.2005 per share. The ex-dividend date of this dividend was Wednesday, September 25th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.